Dmitry Balyasny’s Apogee Therapeutics APGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,665,102
Closed -$221M – 2994
2026
Q2
$221M Buy
1,665,102
+1,226,448
+280% +$110M 0.28% 58
2026
Q1
$36.9M Buy
+438,654
New +$31.9M 0.05% 449
2025
Q4
– Sell
-72,348
Closed -$2.87M – 3058
2025
Q3
$2.87M Sell
72,348
-86,287
-54% -$3.29M ﹤0.01% 1632
2025
Q2
$6.89M Buy
158,635
+45,905
+41% +$1.75M 0.01% 1138
2025
Q1
$4.21M Buy
+112,730
New +$4.36M 0.01% 1331
2024
Q2
– Sell
-3,561
Closed -$237K – 2544
2024
Q1
$237K Buy
+3,561
New +$155K ﹤0.01% 2346

Other funds holding APGE

Dmitry Balyasny's APGE Position: Q3 2026 in Review

Dmitry Balyasny sold out of Apogee Therapeutics (APGE) in Q3 2026, closing a stake of 1,665,102 shares — an estimated $221M sold.

Dmitry Balyasny first reported a position in APGE in Q1 2024 and held it in 6 quarters. The position peaked at $221M in Q2 2026. 2 funds tracked by Wall St. Rank hold APGE as of Q3 2026.

  • Dmitry Balyasny reported no remaining Apogee Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 1,665,102 Apogee Therapeutics shares in Q3 2026, an estimated $221M.
  • Dmitry Balyasny first reported a position in Apogee Therapeutics in Q1 2024 and held it in 6 quarters.
  • Dmitry Balyasny's Apogee Therapeutics position peaked at $221M in Q2 2026.
  • 2 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2026.

Based on Balyasny Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.